A lack of diversity in cell lines used for laboratory studies means underrepresented populations and minorities might not benefit from precision medicines as quickly as people from European ancestry.
Underrepresented populations and minorities will not be able to reap the benefits of precision medicine as quickly as people from European ancestry, according to a new study in Cancer Epidemiology, Biomarkers & Prevention.
Researchers found there is a lack of diversity among cell lines used for laboratory studies to study prostate, breast, and cervical cancers. They looked at 15 commercial cell lines categorized based on the amount of West African, Native American, and European genetic ancestry.
"A lack of diversity is prevalent in every level of biomedicine—from the patient population in clinical trials to the donated samples for scientific investigation," Rick A. Kittles, PhD, director of the Division of Health Equities at City of Hope and senior author of the new study, said in a statement. "How can we expect to narrow the health equity canyon when our basic scientific resources—cell lines for laboratory study—is predominately from people of European ancestry? Minorities like myself are not the primary beneficiaries of most scientific innovations."
The researchers also found that while cell lines described as European ancestry were accurately labeled, those classified as African American were not always accurate and had more of a mixed genetic background. For instance, the E006AA-hT prostate cancer cell line was classified as African American but carried 92% European ancestry. This cell line is used to investigate prostate cancer health disparities. The result of the study means that there is only 1 commercially available African American prostate cancer cell line: MDA-PCa-2b.
A search of the American Type Culture Collection for cell lines from normal and malignant breast tissue found that 71% of the specimens were classified as white, and only 13% were African American. Furthermore, there was only 1 Hispanic and 1 East Indian sample.
Making precision medicine available to all people means having a diverse sample of biospecimens with accurately classified genetic ancestry, Kittles said.
“An important aspect of precision medicine is being able to leverage the genetic background of individuals for disease risk assessment, stratification, prognosis and outcome,” he said. “Here we show that what many investigators thought were classic samples from racially defined individuals wasn't the case.”
Reference
Hooker SE, Woods-Burnham L, Bathina M, et al. Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines [published online February 20, 2019]. Cancer Epidemiol Biomarkers Prev. doi: 0.1158/1055-9965.EPI-18-1132.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More